camrelizumab,rivoceranib
hlb bio group,jiangsu hengrui pharmaceuticals
['apatinib', 'camrelizumab']
camrelizumab plus apatinib . another option for relapsed uterine cancer in second line. 44 %orr . pfs 6.4 months . #asco23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists